A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Breast Neoplasms · Neoplasm Metastasis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 874 (final count)
- Started
- Oct 4, 2021
- Main results expected
- Jun 24, 2024
- Fully finished
- Aug 2027
- Results posted
- Jul 11, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)
Measured over: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Investigator-assessed PFS (Between Arm C and Arm A)
Measured over: Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)
Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)
Measured over: Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04975308 · record last updated 2026-07-22 · checked 2026-11-09 15:42 UTC